Strong alignment: program explicitly targets TechBio + pharma R&D intersection; venture is pre-seed computational drug discovery at this intersection. International scope enables EU participation from France. 3-month hybrid model suits pre-seed stage refining value proposition and partnerships (e.g., Servier pilot).